Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Mycobacterium tuberculosis (Mtb) replicates within host macrophages by adapting to the
stressful and nutritionally constrained environments in these cells. Exploiting these …

The rise of drug resistance has become a major obstacle in treating tuberculosis (TB),
significantly contributing to the increasing disease burden. Therefore, it is essential to study …

Current tuberculosis and non-tuberculous mycobacterial disease guidelines recommend the
use of clofazimine in a 100 mg once-daily dose. The rationale behind this exact dose is not …

Objectives To describe demographics, clinical features, and treatment outcomes of patients
with highly drug-resistant tuberculosis (TB) in Ukraine, and to evaluate risk factors for an …

Tuberculosis (TB) control is complicated by the emergence of drug resistance. Promising
strategies to prevent drug resistance are the targeting of nonreplicating, drug-tolerant …

Tuberculosis is one of the most common infectious diseases in the world, caused by
Mycobacterium tuberculosis. The outbreak of multiple drug-resistant tuberculosis has …

Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally.
Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and …

Introduction The urgent need for new treatments for multidrug-resistant tuberculosis (MDR-
TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) is evident. However, the …

Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global health
and economic burden, ranking among the leading infectious disease causes for mortality [1] …